PT  - JOURNAL ARTICLE
AU  - Hober, Andreas
AU  - Hua, Tran-Minh Khue
AU  - Foley, Dominic
AU  - McDonald, Thomas
AU  - Vissers, Johannes P.C.
AU  - Pattison, Rebecca
AU  - Ferries, Samantha
AU  - Hermansson, Sigurd
AU  - Betner, Ingvar
AU  - Uhlen, Mathias
AU  - Razavi, Morteza
AU  - Yip, Richard
AU  - Pope, Matthew E.
AU  - Pearson, Terry W.
AU  - Anderson, N. Leigh
AU  - Bartlett, Amy
AU  - Calton, Lisa
AU  - Alm, Jessica J.
AU  - Engstrand, Lars
AU  - Edfors, Fredrik
TI  - Rapid and Sensitive Detection of SARS-CoV-2 Infection Using Quantitative Peptide Enrichment LC-MS Analysis
AID  - 10.1101/2021.06.02.21258097
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.02.21258097
4099  - http://medrxiv.org/content/early/2021/10/26/2021.06.02.21258097.short
4100  - http://medrxiv.org/content/early/2021/10/26/2021.06.02.21258097.full
AB  - Reliable, robust, large-scale molecular testing for SARS-CoV-2 is essential for monitoring the ongoing Covid-19 pandemic. We have developed a scalable analytical approach to detect viral proteins based on peptide immunoaffinity enrichment combined with liquid chromatography - mass spectrometry (LC-MS). This is a multiplexed strategy, based on targeted proteomics analysis and read-out by LC-MS, capable of precisely quantifying and confirming the presence of SARS-CoV-2 in PBS swab media from combined throat/nasopharynx/saliva samples.The results reveal that the levels of SARS-CoV-2 measured by LC-MS correlate well with their corresponding RT-PCR readout (r=0.79). The analytical workflow shows similar turnaround times as regular RT-PCR instrumentation with a quantitative readout of viral proteins corresponding to cycle thresholds (Ct) equivalents ranging from 21 to 34. Using RT-PCR as a reference, we demonstrate that the LC-MS-based method has 100% negative percent agreement (estimated specificity) and 95% positive percent agreement (estimated sensitivity) when analyzing clinical samples collected from asymptomatic individuals with a Ct within the limit of detection of the mass spectrometer (Ct ≤30). These results suggest that a scalable analytical method based on LC-MS has a place in future pandemic preparedness centers to complement current virus detection technologies.Competing Interest StatementThe authors declare the following competing financial interest(s): D.F, T.M, J.V, R.P, S.F, I.B, S.H, A.B, L.C are employed by Waters Corporation. M.R, R.Y, M.E.P, T.W.P and N.L.A are employed by SISCAPA Assay Technologies.Clinical TrialDNR - 2020-06395Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Regional ethics board ni Linkoping, SwedenI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe proteomics data have been deposited to Panorama Public [38] (https://panoramaweb.org/sars-cov-2_siscapa.url; login: panoramareviewer{at}gmail.com, pwd: scilifelab), allowing for access to raw files and integrated peak areas from as well as visualization of LC-MRM/MS chromatograms. https://panoramaweb.org/sars-cov-2_siscapa.url